Your browser doesn't support javascript.
loading
The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges.
Gourlay, Annabelle; Noori, Teymur; Pharris, Anastasia; Axelsson, Maria; Costagliola, Dominique; Cowan, Susan; Croxford, Sara; d'Arminio Monforte, Antonella; Del Amo, Julia; Delpech, Valerie; Díaz, Asunción; Girardi, Enrico; Gunsenheimer-Bartmeyer, Barbara; Hernando, Victoria; Jose, Sophie; Leierer, Gisela; Nikolopoulos, Georgios; Obel, Niels; Op de Coul, Eline; Paraskeva, Dimitra; Reiss, Peter; Sabin, Caroline; Sasse, André; Schmid, Daniela; Sonnerborg, Anders; Spina, Alexander; Suligoi, Barbara; Supervie, Virginie; Touloumi, Giota; Van Beckhoven, Dominique; van Sighem, Ard; Vourli, Georgia; Zangerle, Robert; Porter, Kholoud.
Afiliação
  • Gourlay A; University College London, United Kingdom.
  • Noori T; European Centre for Disease Prevention and Control, and.
  • Pharris A; European Centre for Disease Prevention and Control, and.
  • Axelsson M; Public Health Agency of Sweden, Solna.
  • Costagliola D; Sorbonne Universites, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique (IPLESP UMR_S 1136), Paris, France.
  • Cowan S; Statens Serum Institut, Copenhagen, Denmark.
  • Croxford S; Public Health England, London, United Kingdom.
  • d'Arminio Monforte A; ASST Santi Paolo e Carlo University Hospital, Milan, Italy.
  • Del Amo J; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Delpech V; Public Health England, London, United Kingdom.
  • Díaz A; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Girardi E; Istituto Nazionale Malattie Infettive 'L. Spallanzani', Rome, Italy.
  • Gunsenheimer-Bartmeyer B; Robert Koch Institute, Berlin, Germany.
  • Hernando V; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
  • Jose S; University College London, United Kingdom.
  • Leierer G; Medical University Innsbruck, Austria.
  • Nikolopoulos G; Medical School, University of Cyprus, Nicosia.
  • Obel N; Hellenic Center for Disease Control and Prevention, Amarousio, Greece.
  • Op de Coul E; Rigshospitalet, Copenhagen University, Denmark.
  • Paraskeva D; National Institute for Public Health and the Environment, Bilthoven.
  • Reiss P; Hellenic Center for Disease Control and Prevention, Amarousio, Greece.
  • Sabin C; Stichting HIV Monitoring, Amsterdam, and.
  • Sasse A; Academic Medical Center, Amsterdam, The Netherlands.
  • Schmid D; University College London, United Kingdom.
  • Sonnerborg A; Scientific Institute of Public Health, Brussels, Belgium.
  • Spina A; Austrian Agency for Health and Food Safety, Vienna.
  • Suligoi B; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Supervie V; Austrian Agency for Health and Food Safety, Vienna.
  • Touloumi G; National AIDS Unit, Istituto Superiore di Sanita, Rome, Italy; and.
  • Van Beckhoven D; Sorbonne Universites, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique (IPLESP UMR_S 1136), Paris, France.
  • van Sighem A; Medical School, National and Kapodistrian University of Athens, Greece.
  • Vourli G; Scientific Institute of Public Health, Brussels, Belgium.
  • Zangerle R; Stichting HIV Monitoring, Amsterdam, and.
  • Porter K; Medical School, National and Kapodistrian University of Athens, Greece.
Clin Infect Dis ; 64(12): 1644-1656, 2017 Jun 15.
Article em En | MEDLINE | ID: mdl-28369283
BACKGROUND.: The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set a "90-90-90" target to curb the human immunodeficiency virus (HIV) epidemic by 2020, but methods used to assess whether countries have reached this target are not standardized, hindering comparisons. METHODS.: Through a collaboration formed by the European Centre for Disease Prevention and Control (ECDC) with European HIV cohorts and surveillance agencies, we constructed a standardized, 4-stage continuum of HIV care for 11 European Union countries for 2013. Stages were defined as (1) number of people living with HIV in the country by end of 2013; (2) proportion of stage 1 ever diagnosed; (3) proportion of stage 2 that ever initiated ART; and (4) proportion of stage 3 who became virally suppressed (≤200 copies/mL). Case surveillance data were used primarily to derive stages 1 (using back-calculation models) and 2, and cohort data for stages 3 and 4. RESULTS.: In 2013, 674500 people in the 11 countries were estimated to be living with HIV, ranging from 5500 to 153400 in each country. Overall HIV prevalence was 0.22% (range, 0.09%-0.36%). Overall proportions of each previous stage were 84% diagnosed, 84% on ART, and 85% virally suppressed (60% of people living with HIV). Two countries achieved ≥90% for all stages, and more than half had reached ≥90% for at least 1 stage. CONCLUSIONS.: European Union countries are nearing the 90-90-90 target. Reducing the proportion undiagnosed remains the greatest barrier to achieving this target, suggesting that further efforts are needed to improve HIV testing rates. Standardizing methods to derive comparable continuums of care remains a challenge.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Continuidade da Assistência ao Paciente / União Europeia / Erradicação de Doenças Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Continuidade da Assistência ao Paciente / União Europeia / Erradicação de Doenças Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article